NEWS & PRESS
Syndivia is a laureate AstraZeneca's open innovation program - ReAliZe
STRASBOURG (France) – October 2, 2019 – Syndivia is nominated laureate of ReAliZe in the Scientific Innovation category. ReAliZe is an open innovation program of AstraZeneca supporting oncology start-ups and focusing on 4 main areas: data management, scientific innovation, patient care and artificial intelligence.
Syndivia and BFCL publish review of Antibody–Oligonucleotide Conjugates (AOC) as therapeutic, imaging, and detection agents
Syndivia and Biofunctional Chemistry Laboratory announce publication of a review titled “Antibody–Oligonucleotide Conjugates as Therapeutic, Imaging, and Detection Agents” in Bioconjugate Chemistry. The review gives a comprehensive overview of the main applications of antibody-oligonucleotide conjugates (AOC) as well as major synthetic approaches used for their preparation. The review emphasized the importance of the development of novel methods for efficient and reliable generation of AOC, in order to advance their new applications.
Meet us at BIO 2019
Syndivia will be attending the 2019 BIO International Convention that takes place in Philadelphia, PA, USA, on 3-6 June 2019. Contact us on enquiry@syndivia.com, or via the partneringONE® platform to request a meeting and discuss exciting new opportunities in the biopharmaceutical space.
Meet us at PEGS Boston 2019
Syndivia’s CSO, Dr Sergii Kolodych, will present our latest developments at PEGS Summit 2019.
April 8-12, Seaport World Trade Center, Boston, MA.
Syndivia's CSO speaking at PEGS Europe 2018
Syndivia’s CSO, Dr Sergii Kolodych, will be presenting ENACT technology and its application for native protein modification at PEGS Europe 2018, November 12-16, 2018, Lisbon, Portugal.
